Not all GH secretagogues work the same way. Here's a research-based comparison. SERMORELIN (GHRH Analog) - Mechanism: Mimics natural GHRH, signals pituitary to release GH - Evidence level: Highest among secretagogues (was FDA-approved, well-studied) - Administration: Subcutaneous injection - GH release pattern: Maintains natural pulsatile release - What ElevateMD prescribes: Yes — core component of the Longevity Stack CJC-1295 (Modified GHRH Analog) - Mechanism: Extended half-life GHRH analog (with or without DAC modification) - Evidence level: Moderate — clinical studies exist but fewer than Sermorelin - Key difference: Longer half-life means sustained GH elevation vs pulsatile - Note: The DAC version creates continuous GH elevation, which may not be physiologically ideal IPAMORELIN (Ghrelin Mimetic / GHSR Agonist) - Mechanism: Stimulates GH release through a DIFFERENT pathway (ghrelin receptor) - Evidence level: Moderate — clinical studies show selective GH release - Key advantage: Very selective — minimal effect on cortisol and prolactin - Often combined with CJC-1295 for dual-pathway stimulation WHY MECHANISM MATTERS Sermorelin works through the GHRH pathway. Ipamorelin works through the ghrelin pathway. These are different biological systems with different downstream effects. OUR APPROACH We start with what has the strongest evidence (Sermorelin) and build from there based on your labs and response. We don't stack compounds without clinical justification. What questions do you have about the differences between these compounds?

BPC-157 (Body Protection Compound-157) is one of the most discussed peptides in longevity communities. Here's what the published research actually shows — and what it doesn't. WHAT IS BPC-157? A 15-amino acid peptide originally isolated from human gastric juice. It's a stable fragment of a naturally occurring protein called BPC (Body Protection Compound). WHAT PRECLINICAL STUDIES SHOW Animal and cell studies have shown effects on: - Tendon and ligament healing acceleration - Muscle repair and regeneration - Gastrointestinal mucosal protection - Anti-inflammatory pathways - Nitric oxide system modulation - Angiogenesis (new blood vessel formation) THE CRITICAL DISTINCTION Almost all BPC-157 research is PRECLINICAL — meaning animal studies and cell cultures, not human clinical trials. Why this matters: - Many compounds that work in animals don't translate to humans - Dosing from animal studies doesn't directly convert to human dosing - Safety profiles established in rats may not apply to humans - Long-term human safety data is essentially nonexistent WHAT CLINICAL (HUMAN) DATA EXISTS Very limited. A few small trials exist, primarily in gastrointestinal applications. The body of human evidence is nowhere near the level of evidence for compounds like Sermorelin. OUR POSITION We discuss BPC-157 research honestly because our community is intelligent enough to distinguish between preclinical promise and clinical proof. We don't pretend mouse studies equal medical evidence. But we also don't dismiss promising preclinical data. What aspects of BPC-157 research interest you most? Let's discuss the science.

Welcome to ElevateMD's Peptide Research Corner. This space exists for one purpose: discussing published peptide research with scientific rigor. What this space IS: - A place to discuss peer-reviewed research on therapeutic peptides - A space for questions about mechanisms of action, study findings, and regulatory developments - An educational resource led by physicians who follow the science AND the regulations What this space IS NOT: - Medical advice (all clinical decisions happen through your physician) - A place to source, buy, or discuss obtaining peptides outside medical supervision - A promotional channel — we don't make claims beyond what the evidence supports Ground rules: 1. Cite your sources when sharing research 2. Distinguish between preclinical (animal/cell) and clinical (human) evidence 3. Use correct regulatory language — "HHS Secretary Kennedy stated his intention to reclassify" is accurate. "FDA approved" is not. 4. Ask questions freely — "we don't know yet" is a valid and honest answer Our physicians will participate regularly. Let's build the most evidence-based peptide discussion on the internet.